<DOC>
	<DOCNO>NCT00594087</DOCNO>
	<brief_summary>The purpose study determine people multiple sclerosis ( MS ) fatigue disrupt sleep , suggest previous study , whether treat disruption sleep improves fatigue . Eszoplicone , new drug FDA approve treatment insomnia , use control sleep disturbance MS patient fatigue . The study last 7 week , 5 involve medication . You take eszopiclone placebo ( sugar pill ) , keep sleep diary wear actigraph , device size digital watch monitor record sleep activity . You randomly choose get either placebo medication . Half subject get placebo half eszopiclone . The decision make pharmacist ( know ) accord randomization table . Neither investigate physician know whether sugar pill medication . At begin conclusion study ask fill 2 questionnaire evaluate fatigue depression undergo memory speech test . The test take 2 hour . Actigraphy wrist-worn , watch like device record activity wake sleep without application sensor . It consist movement detector , record movement non-movement data week two . You wear continuously wakefulness sleep go routine daily activity . You take go shower , bathe swim . A sleep log graph , 2 3 week , record bedtime , approximate sleep time , time duration awakening sleep period , final awakening time , nap take day best knowledge . You also ask avoid get pregnant . If woman may potential get pregnant pregnancy test may perform begin study , receive medication , first follow visit end study .</brief_summary>
	<brief_title>Eszopiclone Improving Sleep Multiple Sclerosis ( MS )</brief_title>
	<detailed_description>The purpose study determine people multiple sclerosis ( MS ) fatigue disrupt sleep , suggest previous study , whether treat disruption sleep improves fatigue . Eszoplicone , new drug FDA approve treatment insomnia , use control sleep disturbance MS patient fatigue . The study last 7 week , 5 involve medication . You take eszopiclone placebo ( sugar pill ) , keep sleep diary wear actigraph , device size digital watch monitor record sleep activity . You randomly choose get either placebo medication . Half subject get placebo half eszopiclone . The decision make pharmacist ( know ) accord randomization table . Neither investigate physician know whether sugar pill medication . At begin conclusion study ask fill 2 questionnaire evaluate fatigue depression undergo memory speech test . The test take 2 hour . Actigraphy wrist-worn , watch like device record activity wake sleep without application sensor . It consist movement detector , record movement non-movement data week two . You wear continuously wakefulness sleep go routine daily activity . You take go shower , bathe swim . A sleep log graph , 2 3 week , record bedtime , approximate sleep time , time duration awakening sleep period , final awakening time , nap take day best knowledge . You also ask avoid get pregnant . If woman may potential get pregnant pregnancy test may perform begin study , receive medication , first follow visit end study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>1 . Male female subject age 18 64 inclusive . 2 . Female subject must surgically sterile , least 1 year post menopausal , agree use medically acceptable form birth control throughout study 2 week follow last study visit . 3 . Diagnosis relapsingremitting MS 4 . MS MS symptom must stable ( evidence worsen exacerbation ) least 3 month prior screen visit . The date last recorded exacerbation capture enrollment . 5 . EDSS score &lt; /= 5 6 . Diagnosis fatigue base fatigue questionnaire , specifically Fatigue Descriptive Scale ( FDS ) score five high consider indicative fatigue ( range 013 ) 7 . Actigraphic evidence sleep disturbance define sleep latency 30 minute longer , and/or total sleep time le 6.5 hour . 8 . Finally CESD score 20 ( 20 suggestive Major Depression ) 1 . Pregnant breastfeed woman 2 . Subjects history substance and/or alcohol abuse dependence within 5 year prior screen . 3 . Subjects sole caretaker infant young child may sedate middle night case need get take care infant child . 4 . Patients past history allergy eszopiclone Zopiclone . 5 . Patients primary progressive Multiple Sclerosis . 6 . Subjects impaired cognition measure Mini Mental State Examination ( MMSE ) score 26 less 7 . Subjects history suggestive another primary sleep disorder include OSAS , PLMS , RLS 8 . Any patient know active DSMIV axis I ( i.e . schizophrenia , etc ) psychiatric disorder would compromise investigator 's ability evaluate safety efficacy study medication . 9 . Patients 65 year old old drug 3 mg dose FDA approve used age group .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>